Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)
Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –
Jazz Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Jazz Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $425.96M. For fiscal 2025 it was -$430.24M, down 160.0% from the year before. The highest annual figure on record is $716.63M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$430.24M | -160.0% |
| FY2024 | Dec 31, 2024 | $716.63M | +23.9% |
| FY2023 | Dec 31, 2023 | $578.58M | – |
| FY2022 | Dec 31, 2022 | -$65.53M | -138.5% |
| FY2021 | Dec 31, 2021 | $170.28M | -55.0% |
| FY2020 | Dec 31, 2020 | $378.07M | -29.0% |
| FY2019 | Dec 31, 2019 | $532.37M | -13.4% |
| FY2018 | Dec 31, 2018 | $614.84M | +16.3% |
| FY2017 | Dec 31, 2017 | $528.84M | -10.6% |
| FY2016 | Dec 31, 2016 | $591.65M | +16.4% |
| FY2015 | Dec 31, 2015 | $508.22M | +159.8% |
| FY2014 | Dec 31, 2014 | $195.59M | -42.5% |
| FY2013 | Dec 31, 2013 | $340.31M | +72.0% |
| FY2012 | Dec 31, 2012 | $197.84M | +54.8% |
| FY2011 | Dec 31, 2011 | $127.83M | +121.2% |
| FY2010 | Dec 31, 2010 | $57.79M | +262.8% |
| FY2009 | Dec 31, 2009 | $15.93M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$413.40M | -819.0% |
| Q2 FY2026 | Jun 30, 2026 | $248.20M | – |
| Q1 FY2026 | Mar 31, 2026 | $336.60M | – |
| Q4 FY2025 | Dec 31, 2025 | $254.56M | +33.4% |
| Q3 FY2025 | Sep 30, 2025 | $57.50M | -77.9% |
| Q2 FY2025 | Jun 30, 2025 | -$686.40M | -444.2% |
| Q1 FY2025 | Mar 31, 2025 | -$55.90M | -184.4% |
| Q4 FY2024 | Dec 31, 2024 | $190.77M | +55.7% |
| Q3 FY2024 | Sep 30, 2024 | $260.21M | +50.9% |
| Q2 FY2024 | Jun 30, 2024 | $199.44M | +26.5% |
| Q1 FY2024 | Mar 31, 2024 | $66.21M | -47.5% |
| Q4 FY2023 | Dec 31, 2023 | $122.50M | – |
| Q3 FY2023 | Sep 30, 2023 | $172.39M | +596.2% |
| Q2 FY2023 | Jun 30, 2023 | $157.64M | +84.3% |
| Q1 FY2023 | Mar 31, 2023 | $126.06M | +44.0% |
| Q4 FY2022 | Dec 31, 2022 | -$263.39M | -633.4% |
| Q3 FY2022 | Sep 30, 2022 | $24.76M | -12.7% |
| Q2 FY2022 | Jun 30, 2022 | $85.55M | – |
| Q1 FY2022 | Mar 31, 2022 | $87.55M | -46.0% |
| Q4 FY2021 | Dec 31, 2021 | $49.38M | -71.5% |
| Q3 FY2021 | Sep 30, 2021 | $28.37M | -85.5% |
| Q2 FY2021 | Jun 30, 2021 | -$69.59M | -135.1% |
| Q1 FY2021 | Mar 31, 2021 | $162.12M | – |
| Q4 FY2020 | Dec 31, 2020 | $173.41M | +183.1% |
| Q3 FY2020 | Sep 30, 2020 | $196.21M | +47.4% |
| Q2 FY2020 | Jun 30, 2020 | $198.13M | -3.0% |
| Q1 FY2020 | Mar 31, 2020 | -$189.67M | -241.8% |
| Q4 FY2019 | Dec 31, 2019 | $61.25M | -66.9% |
| Q3 FY2019 | Sep 30, 2019 | $133.10M | -29.5% |
| Q2 FY2019 | Jun 30, 2019 | $204.28M | +33.3% |
| Q1 FY2019 | Mar 31, 2019 | $133.74M | +52.3% |
| Q4 FY2018 | Dec 31, 2018 | $185.06M | +31.1% |
| Q3 FY2018 | Sep 30, 2018 | $188.78M | +118.4% |
| Q2 FY2018 | Jun 30, 2018 | $153.20M | -7.2% |
| Q1 FY2018 | Mar 31, 2018 | $87.81M | -35.5% |
| Q4 FY2017 | Dec 31, 2017 | $141.21M | -14.7% |
| Q3 FY2017 | Sep 30, 2017 | $86.45M | – |
| Q2 FY2017 | Jun 30, 2017 | $165.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $136.14M | – |
| Q4 FY2016 | Dec 31, 2016 | $165.50M | – |
See a number that looks wrong?